Background: Data are limited regarding the clinical effectiveness and safety of 27 intravenous colistin for treatment of infections by multidrug-resistant gram-negative 28 bacilli (MDR-GNB) in the paediatric intensive care unit (PICU). 29
Introduction 52
The increased incidence of infections due to multidrug-resistant (MDR) or 53 extensively-drug resistant (XDR) gram-negative bacilli (GNB), has a significant 54 impact on patient safety and public health [1, 2] . Given the paucity of effective 55 antibiotics that are either available or in clinical development, clinicians have resorted 56 to the use of older agents and combinational therapies for treatment of these infections 57 [3] . 58
Although epidemiological data in paediatric settings are limited, studies 59 worldwide show that the antibiotic resistances of GNB are increasing at an alarming 60 rate. For example, a recent report from the Antibiotic Resistance and Prescribing in 61 European Children (ARPEC) project, demonstrated high rates of resistance to 62 commonly used antibiotic classes in children, especially for Escherichia coli, 63
Klebsiella pneumoniae and Pseudomonas aeruginosa [4] , while a national 64 surveillance study among children between 1-17 years of age, revealed a two-fold 65 increase of carbapenem-resistant P. aeruginosa in children in the USA from 1999 to 66 2012 [5] . In another study in European paediatric and neonatal intensive care units 67 (ICU), resistance rates among GNB in intra-abdominal infections were higher than 68 those recorded in non-ICU wards, with MDR rates reaching as high as 13.5% for P. 69 aeruginosa and 40.5% for K. pneumoniae isolates, whereas the highest MDR rates 70 were noted in Central (24.5% of isolates) and Southeast (11.5% of isolates) Europe 71 [6] . Combinations of antibiotics are often necessary to treat these infections, and in 72 endemic areas these combinations may even be used empirically, prior to 73 confirmation of antibiotic susceptibilities. The limited clinical experience with the use 74 of such treatment strategies in children and the lack of clinical trials involving use of 75 new antibiotics in paediatric populations [7] further aggravate the situation. 76
Colistin, which was discovered in 1949 and used since the 1950s has found a 77 recent resurgence in use for treatment of infections by MDR-and XDR-GNB [8] . 78
Although the dosing and safety profile of colistin have been extensively studied in 79 adults, several issues remain unresolved in paediatric patients, particularly the 80 pharmacokinetics and optimal dosing of children of different ages [8] . 81
The aim of this systematic review was to evaluate the available evidence 82 concerning the clinical effectiveness and safety of colistin in the treatment of 83 infections due to MDR-GNB in the PICU. 84 85
Material and methods 86

Data Sources and Search 87
This review adopted the Preferred Reporting Items for Systematic Reviews and Meta-88 Analyses (PRISMA) guidelines [9] . We performed a literature search in PubMed, 89
Scopus and Embase databases from 2000 through 2018 (last day of search was 90 January 31 st , 2018). The search term algorithm applied in PubMed was: (colistin OR 91 polymyxin E) AND (child* OR pediatric* OR paediatric* OR toddler* OR 92 adolescent*); whereas in Scopus and EMBASE the algorithm was: (colistin OR 93 polymyxin B) AND (child OR children). The references of articles found in this 94 manner were subsequently also searched for relevant articles that could meet the 95 PRISMA criteria. 96
97
Study selection 98
Articles were eligible for inclusion, provided they fulfilled the following criteria: 99 inclusion of at least 5 paediatric (defined as ≥ 1 month and ≤ 18 years of age) patients, 100 and the use of intravenous colistin for treatment of infections due to MDR, XDR or 101 pandrug-resistant GNB in a PICU setting. According to published definitions, a 102 multidrug-resistant (MDR) pathogen is one that is resistant to at least 3 antibiotic 103 classes, an extensively-drug-resistant (XDR) pathogen is resistant to all except one or 104 two antibiotic classes, and a pandrug-resistant (PDR) pathogen is resistant to all 105 antibiotic classes [1] . The following studies were excluded from analysis: studies 106 conducted exclusively in patients with cystic fibrosis; studies that did not include 107 colistin treatment outcomes; studies that included only neonates or were performed in 108 a neonatal ICU; studies performed outside of the PICU; studies that used colistin for 109 treatment of diarrhoea, for decontamination, or for prophylaxis; studies that used 110 polymyxin B or polymyxin E formulations; studies exclusively concerning topical, 111 oral, intraventricular, or intrathecal administration of colistin; conference abstracts, 112 letters to the editor, articles without new data and reviews, and studies published in 113 languages other than English. Authors of included studies were contacted for further 114 clarifications when needed. 
Statistical analysis 143
We calculated the summary mortality rate and corresponding 95% confidence interval 144 (CI), using the random-effects model with arcsine transformation for proportions [12] . 145
We assessed statistical heterogeneity using the I2 statistic Table 1 . 167 168
Type of infections and isolated pathogens 169
The most common infections that warranted use of colistin were lower respiratory 170 tract infections (primarily ventilator-associated pneumonia), followed by bloodstream 171 infection, urinary tract infection, central nervous system infection (including external 172 ventricular drainage-associated ventriculitis or meningitis), and wound infection; sites 173 from which these GNB were isolated are presented in Table 1 all-cause mortality was 29.5% (95% CI 21.7-38.1%, I 2 =64.7%; Figure 2 ). In 6 studies 195 that reported an association between mortality and infection [14-17,19,20], the 196 infection-related mortality was 16.6% (95% CI 12.2-21.5%, I 2 =13.1%,; Figure 3 ). 197
198
Clinical outcomes, microbiological eradication, and adverse events 199
All studies provided information on secondary outcomes ( Table 2) Data regarding adverse events were reported in all seven studies (Table 3) resulting in increased morbidity and mortality [2, 3] . Colistin, to which many of these 228 MDR-GNB retain sensitivity, has gained increased use over the last decade [8] , a fact 229 that is supported by the observation that all included studies were published after 230 2009. In this systematic review, we found that colistin use had a relatively low rate of 231 adverse events and resulted in favourable clinical outcome in 73.1% of paediatric 232 patients with MDR-GNB infections hospitalised in a PICU setting, although the 233 pooled and infection-related mortality rates were 29.5% and 16.6% respectively. It is 234 also worth noting that the majority of included studies were conducted in countries 235 that are known to have a high prevalence of MDR-GNB, signifying the importance of 236 prudent use of colistin, to preserve its efficacy against these pathogens. 237
Our results demonstrate that the majority of MDR-GNB infections in the 238 PICU treated with colistin were lower respiratory tract infections (and especially 239 ventilator-associated pneumonia). Furthermore, we show that A. baumannii was the 240 predominant pathogen, and most treated patients possessed significant comorbidities. There are however, critical differences between these two studies: in the other study, 247 not all patients were critically ill, MDR pathogens were infrequent, a proportion of 248 patients were receiving systemic colistin for prophylaxis rather than treatment, and the 249 majority of included studies were case reports. In support of our contention that these 250 features may dramatically alter the mortality rates, adults treated with colistin for 251 infections by carbapenem-resistant GNB had rates of clinical cure/improvement and 252 mortality that were more comparable to what we report, with estimated pooled 253 mortality rates between 33.8% -35.7% [28, 29] . 254
As far as adverse events are concerned, colistin demonstrated a relatively good 255 rate of tolerability. The most frequently reported adverse event was nephrotoxicity, 256 detected in a small proportion of paediatric patients (6.1%). However, a clear causal 257 association with colistin could not be ascertained, since most of these patients 258 received concomitant nephrotoxic agents or had underlying conditions that 259 compromised renal function. These are factors that have been previously associated 260 with colistin-related nephrotoxicity in adults [30] . Of note, the reversibility of kidney 261 injury after cessation or dose adjustment of colistin, supports the necessity for 262 continuous awareness and frequent monitoring of renal function. Neurotoxicity 263 complicated only 0.5% of paediatric patients, and other adverse events were reported 264 in a small proportion. We believe that the lower rates of acute kidney injury and 265 neurotoxicity [27] reported in the previous systematic review of colistin use in 266 children are again attributable to the differences in the study characteristics. However, 267 it is worthy to note that the adverse event profile of colistin use in adults is different; 268 in a recent meta-analysis regarding the use of colistin in MDR-GNB infections, 269 colistin-related nephrotoxicity was noted to be much higher (19.2%), while 270 neurotoxicity was not reported [28] . 271
The notable difference in rates of nephrotoxicity highlights the observation 272 that during childhood, various physiologic alterations affect drug pharmacokinetics 273 (e.g. volume of distribution, protein binding and renal clearance) and thus, 274 conclusions derived from adult studies do not readily apply to paediatric populations 275 [31] , thus highlighting the need for future studies regarding the pharmacodynamics of 276 colistin therapy in paediatric patients. Indeed, the need for a loading dose and the 277 optimal dosing of colistin is likely to vary between different age groups according to 278 renal function and body weight, or body surface area [31] . In support of this notion, 279 adult cases of nephrotoxicity have been associated with excessive colistin dosage, 280 owed to calculation of doses based on ideal body weight rather than actual body 281 weight [32] . Finally, future paediatric studies should employ strict definitions 282 regarding colistin-related clinical outcomes and adverse events, in order to better 283 evaluate the side effect profile of colistin and these studies should report all potential 284 colistin-related side effects instead of focusing primarily on the historically reported 285 ones (nephrotoxicity and neurotoxicity). 286
In closing, we would like to acknowledge two limitations of our study. Firstly, 287 the studies reported herein were all cohort studies; while this diminishes the quality of 288 evidence, we also cannot exclude an outcome reporting bias favouring the reporting 289 of successful treatments. Secondly, in one study [17] infection episodes were reported 290 rather than infected patients, making interpretations from this study difficult to 291 correlate to the number of affected children. Despite its shortcomings, our study 292 argues that colistin may be relatively safe to use in children with severe MDR-GNB 293 infections in which therapeutic options are limited. 294 295
Conclusions 296
In an era of increasing antimicrobial resistance, the present systematic review 297 suggests that colistin for infections by MDR-GNB in paediatric patients in the PICU 298 Τ Β =tuberculosis; TMP-SMX-trimethoprim-sulfamethoxazole; UTI=Urinary tract infection; VAP=Ventilator-associated pneumonia; y=years. a Data are provided as medians (range) unless otherwise specified. b Some infections were polymicrobial. c All presented data refer to MDR GNB unless otherwise specified. d Two patients were not admitted to the PICU during colistin administration 
